Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs uniQure N.V. Ordinary Shares (QURE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.88B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 6.1× uniQure N.V. Ordinary Shares's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| KYMR | QURE | |
|---|---|---|
Market Cap | $8.88B | $1.45B |
Volume | 1,028,790 | 3,323,243 |
Sector | Health | Health |
52-Week High | $127.31 | $70.59 |
52-Week Low | $55.80 | $9.03 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $8.27B | $707.46M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →
